Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2-negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy
Publication
, Conference
Nixon, AB; Howard, L; Kar, A; Liu, Y; Brady, JC; Niedzwiecki, D; Strickler, JH; Rucevic, M; Uronis, HE
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Nixon, A. B., Howard, L., Kar, A., Liu, Y., Brady, J. C., Niedzwiecki, D., … Uronis, H. E. (2024). Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2-negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Nixon, Andrew B., Lauren Howard, Amrita Kar, Yingmiao Liu, John C. Brady, Donna Niedzwiecki, John H. Strickler, Marijana Rucevic, and Hope Elizabeth Uronis. “Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2-negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Nixon AB, Howard L, Kar A, Liu Y, Brady JC, Niedzwiecki D, et al. Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2-negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Nixon, Andrew B., et al. “Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2-negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Nixon AB, Howard L, Kar A, Liu Y, Brady JC, Niedzwiecki D, Strickler JH, Rucevic M, Uronis HE. Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2-negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences